newsfilter
← Latest News
Earnings Call Transcripts·

JEFFERIES GLOBAL HEALTHCARE CONFERENCE IN LONDON - CORBUS PHARMACEUTICALS HOLDINGS INC

  • Explicit Guidance:

    • No formal numerical financial guidance (revenue, EPS, capex) provided.
    • Oral Oncology (Nectin-4 ADC): Accelerated approval expected for oropharyngeal cancer in second half of 2028, contingent on BLA submission following sufficient ORR data and OS follow-up in the first half of 2028.
    • Obesity Program: Expected to target >10% weight loss at 52 weeks, benchmarked against a trajectory similar to Mounjaro and positioned between Orforglipron and oral Wegovy efficacy.
  • Business-Segment Outlook:

    • Oncology (Tempo-1): Study enrollment in second-line oropharyngeal cancer is ongoing; expect data readout and sufficient follow-up by first half of 2028 to support submission.
    • Oncology (Frontline): Anticipates enrollment for the frontline combination with Pembro will be overwhelmingly completed or finished by the time the competitor (PETO) gains market traction, minimizing patient competition in the second-line setting.
    • Obesity: Phase 1B study (250 patients) has concluded; next steps include observing 52-week data to confirm durability of weight loss and exploring combination therapies (specifically Orforglipron).
    • Partner (China/CSBC): Partner CSBC has initiated a Phase 3 trial in cervical cancer; program timelines and data readouts in China are expected to align with Corbus' safety profile.
  • Market and Competitive Outlook:

    • Competitive Landscape (Oncology): Views current second-line oropharyngeal standard of care as a "desert" with poor outcomes; anticipates coexistence with PETO if CRB701 demonstrates a significant efficacy delta in the oral pharyngeal population.
    • Differentiation Strategy: Positions product against PETO (frontline) and Pixie Bio's PIXIS-007 (second-line); highlights that PIXIS targets HPV-negative patients (where Corbus has a different profile) while focusing Corbus on the HPV-positive and anatomical oral pharyngeal cohort where P16 data is readily available.
    • Market Dynamics: Anticipates that PETO's focus on the frontline setting will remove competitive pressure for Corbus' second-line program, leaving the frontline oral pharyngeal space as the primary battleground for coexistence.
    • Pricing/Adoption: Notes high KOL demand for orthogonal mechanisms to GLP-1s (obesity) and Nectin-4 ADCs (oncology), suggesting strong market receptivity for novel mechanisms.
  • Macro / Industry Outlook:

    • Regulatory: Aligns regulatory strategy with Genmab's successful approach; expects FDA to accept ORR >30% as a clinically desirable threshold for second-line accelerated approval.
    • Clinical Standards: Anticipates KOL consensus requiring ORR >50% for clinical relevance in the frontline setting.
    • Safety Standards: Identifies ocular toxicity (keratitis/dry eye) as a manageable, transient event common to ADCs, contrasting it favorably against the irreversible nature of peripheral neuropathy seen in other classes (e.g., Padcev).
    • Regional Regulatory Nuances: Notes a specific Chinese FDA peculiarity regarding dosing regimens (2.4mg Q2W vs. 3.6mg Q3W) for cervical cancer, though data remains indistinguishable from Corbus' standard.
  • Strategic Initiatives:

    • Pipeline Expansion: Moving from Phase 1/2 data to Phase 3 registrational studies in second-line oropharyngeal cancer; preparing for BLA submission.
    • Combination Therapy: Actively seeking data and partnerships for obesity drug combinations, specifically with Orforglipron, to enhance efficacy.
    • Product Naming: Officially rebranded the Nectin-4 ADC as Sutantagidotin (CRB701) to support commercial positioning.
    • Geographic Focus: Maintains primary focus on oral pharyngeal cancer (anatomical selection) rather than HPV-status stratification to ensure real-world generalizability and avoid artificial skewing.
  • Risks and Headwinds to Outlook:

    • Safety Events: Ocular events (keratitis, dry eye) occurred in approximately one-third of patients, leading to temporary interruptions or dose reductions (average ~1 week); risk of non-adherence or discontinuation if management is suboptimal.
    • Efficacy Dilution: Potential for HPV-negative patients to dilute treatment effect compared to HPV-positive cohorts, though retrospective stratification is expected to clarify benefit.
    • Competitive Disruption: PETO data in the frontline setting remains a critical unknown; if PETO demonstrates superior efficacy in HPV-positive oral pharyngeal patients, it could encroach on Corbus' frontline opportunity.
    • Timeline Risk: Accelerated approval pathway relies on achieving sufficient ORR; failure to clear the 30% threshold (second-line) or 50% threshold (frontline) could delay or block submission.
    • Regulatory Uncertainty: Reliance on FDA alignment with Genmab's strategy carries the risk of unexpected regulatory hurdles despite current "sensible" assumptions.
  • Management Tone on the Future:

    • Confidence: High confidence in the Phase 3 design and statistical assumptions, explicitly stating they are "emulating" Genmab's "enviable" strategy.
    • Optimism: Describes the obesity mechanism feedback as "immensely informative and really uniform" with "high degree of comfort" from KOLs.
    • Strategic Clarity: Expresses clear conviction that second-line is a "desert" and that their differentiated approach (anatomical selection + orthogonal mechanism) offers a distinct value proposition against competitors like PIXIS and PETO.
    • Risk Mitigation: Tone suggests ocular toxicity is a "price to pay" for hyper-stable ADCs but is manageable with standard protocols (eye drops, interruptions), minimizing long-term patient impact.
  • Miscellaneous:

    • Patient Population: Approximately 85% of oral pharyngeal patients are HPV-positive; the company will enroll regardless of status but utilize P16 for retrospective stratification.
    • Dosing Regimens: Corbus utilizes 3.6mg Q3W; partner CSBC utilizes 2.4mg Q2W in China, a divergence attributed to local regulatory requirements rather than efficacy differences.
    • Safety Timeline: Irritability in the obesity program occurred immediately at treatment initiation (mostly at 20mg dose), resolved quickly, and resulted in zero discontinuations.
Company
CORBUS PHARMACEUTICALS HOLDINGS INC
Keywords
CORBUS PHARMACEUTICALS HOLDINGS INC